Paper Details

  1. Home
  2. Paper Details

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.

Author: AmarNiran J, CartwrightRobert C, HoffmanHal M, KivitzAlan J, SooYuhwen, ThroneMartin L, WeinsteinSteven P

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Long-term treatment with rilonacept, an interleukin-1 inhibitor, for up to 96 weeks resulted in significant improvements in clinical signs and symptoms of Cryopyrin-associated periodic syndromes (CAPS). The treatment also normalized inflammatory biomarkers and exhibited a favorable safety profile in both adults and children.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Cryopyrin-associated periodic syndromes (CAPS) are rare, inherited autoinflammatory disorders associated with considerable hardship to patients. The interleukin-1 inhibitor rilonacept has been shown to be well-tolerated and effective in preventing CAPS symptoms in 2 pivotal studies. OBJ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2012.09.009

データ提供：米国国立医学図書館（NLM）

Rilonacept: A Long-Term Solution for Cryopyrin-Associated Periodic Syndromes

Cryopyrin-associated periodic syndromes (CAPS) are a group of rare, inherited disorders characterized by recurrent episodes of inflammation. These syndromes can significantly impact quality of life, leading to pain, fever, and other symptoms. This study investigates the long-term efficacy and safety of [rilonacept], an [interleukin-1 inhibitor], in treating CAPS. The results show that rilonacept, administered weekly for up to [96 weeks], significantly reduced the severity and frequency of CAPS symptoms.

Rilonacept: A Beacon of Hope for CAPS Patients

The study demonstrates that rilonacept provides long-term relief from CAPS symptoms. This treatment significantly reduced key symptom scores, normalized inflammatory markers, and improved overall well-being for patients with CAPS. This research offers promising hope for those living with these rare and debilitating disorders.

Living with CAPS: A Journey Towards Better Health

As a camel who has encountered the occasional prickly cactus, I can empathize with the challenges faced by those living with CAPS. This research offers valuable insights into the potential of [rilonacept] to improve the quality of life for CAPS patients. It underscores the importance of early diagnosis and treatment for individuals with these rare disorders.

Dr.Camel's Conclusion

This study highlights the long-term efficacy and safety of rilonacept in managing CAPS. This research offers hope for individuals living with these rare and challenging disorders, providing a pathway towards improved quality of life.

Date :
  1. Date Completed 2013-03-22
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

23031624

DOI: Digital Object Identifier

10.1016/j.clinthera.2012.09.009

Related Literature

Article Analysis
・Effects of rilonacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.